Send to

Choose Destination
Fetal Diagn Ther. 2016;39(4):287-91. doi: 10.1159/000441027. Epub 2015 Oct 1.

First-Trimester Placental Growth Factor in Screening for Gestational Diabetes.

Author information

Department of Obstetrics and Gynecology, University Hospital and University of Bern, Bern, Switzerland.



The aim of this study was first to assess whether first-trimester serum concentrations of placental growth factor (PlGF) differ between patients with and without gestational diabetes (GDM) and second to test whether there is a correlation between glycosylated hemoglobin (HbA1c), a factor recently shown to be useful in predicting GDM, and PlGF.


PlGF was measured at 8-14 weeks with the Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany). Absolute values were converted to multiples of the median using the software provided by the Fetal Medicine Foundation London. GDM was diagnosed using internationally accepted criteria. HbA1c levels were quantified using the TOSOH G7 automated hemoglobin analyzer.


From January to December 2014, 328 women were included in the study, 51 (15.5%) of whom developed GDM. First-trimester PlGF quantification does not discriminate between women at risk to develop GDM and controls, while HbA1c is able to do so. No correlation was found between PlGF and HbA1c.


Our findings do not lend support to the hypothesis that early PlGF values are different in women who later develop GDM.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for Bern Open Repository and Information System
Loading ...
Support Center